Summary
The single dose pharmacokinetics of flutoprazepam and its active N-desalkyl metabolite were determined in 8 normal subjects by using newly developed, highly sensitive, GC-MS and HPLC techniques. Following a 2 mg dose of the drug, the concentrations of unchanged flutoprazepam in serum were extremely low (below 5 ng/ml at 2 h) and declined rapidly to undetectable levels within 6–9 h after dosing. At all sampling times, the serum concentration of the N-dealkylated metabolite (N-desalkylflurazepam) was much greater than that of the parent compound. This metabolite appeared in serum rapidly (within 2 h), reached a peak between 2 and 12 h and declined slowly, with an elimination half-life of about 90 h on average. The serum concentration of two additional putative metabolites (3-hydroxy-flutoprazepam and N-desalkyl-3-hydroxy-flutoprazepam) was below the limit of detection (2 ng/ml) in all samples. Mild CNS effects (documented by prolonged choice reaction time) were present at 2 and 4 h but were no longer detectable at 9 h. It is suggested that unchanged flutoprazepam is unlikely to contribute significantly to clinical effects and that the drug exerts its therapeutic activity through conversion to the slowly eliminated N-desalkyl metabolite.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ueki S., Sukamoto T., Watanabe S.,et al. (1982): Behavioural effects of flutoprazepam (KB S09) and its metabolites. Pholia Pharmacol. Jpn., 80, 15–30.
Kanebo Pharmaceuticals Ltd., unpublished data.
Tsutsui S., Nisbida K., Namba T., Saito T. (1982): Clinical study of KB 509 (flutoprazepam) on psychosomatic disorders and neuroses (double-blind test). Jpn. Pharmacol. Ther., 10, 6337–6351.
Kudo Y.,TanakaS. (1980): Clinical pharmacology of KB 509. In: Turner P., Padgham C. (eds), Abstracts World Conference on Clinical Pharmacology and Therapeutics, London, Abstract 0242.
Midorikawa T., Miura S., Sato M., Sakurai S., Awata N. (1982): The metabolic fate of 7-cbloro-l-cyclopropyl-methyll, 3-dihydro-5-(2-fluorophenyl)-2H-1,4-benzodiazepin-2-one (KB 509). I. Metabolism in dogs, mice and rats. Iyakukin. Kenkyu, 13, 309.
Sakurai S., Miura S., Sato M., Midorikawa T., Awata N. (1982): The metabolic fete of 7-chloro-l-cyclopropyl-methyl-1,3-dfliydro-5-(2-fluorophenyl)-2H-1,4-enzodiazepin-2-one (KB 509). II. Absorption, distribution and excretion in rats, mice and dogs. Iyakukin. Kenkyu, 13, 309.
Kageyama T. Phase I study of flutoprazepam (KB 509). Single dose study 1987. Kanebo Pharmaceuticals Ltd., Unpublished data
Hindmarch I. (1980): Psychomotor function and psychoactive drugs. Br. J. Clin. Pharmacol., 10, 189–209.
Brodie R.R., Chassaud D.F., Taylor T. (1981): Concentrations of N-descyclopropylmethylprazepam in whole blood, plasma and milk after administration of prazepam to humans. Biopharm. Drug Dispos., 2, 59–68.
Greenblatt D.J., Divoll M., Harmatz J., MacLaughlin D.S., Shatter Ri. (1981): Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs. Clin. Pharmacol. Ther., 30, 475–486.
Greenblatt D.J., Shader R.I., Abemethy D.R. (1983): Current status of benzodiazepines. New Engl. J. Med., 309, 354–358.
Schwartz M.A., Postma E. (1970): Metabolism of flurazepam, a benzodiazepine, in man and dog. J. Pharm. Sei., 59, 1800–1806.
Kaplan S.A., de Silva J.A.F., Jack M.X., et al. (1973): Blood level profile in man following chronic oral administration of flurazepam hydrochloride. J. Pharm. Sei, 62, 1932–1935.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Barzaghi, N., Leone, L., Monteleone, M. et al. Pharmacokinetics of flutoprazepam, a novel benzodiazepine drug, in normal subjects. Eur. J. Drug Metab. Pharmacokinet. 14, 293–298 (1989). https://doi.org/10.1007/BF03190114
Received:
Issue date:
DOI: https://doi.org/10.1007/BF03190114
